Hurdle
2 known investors
Hurdle provides diagnostic testing infrastructure for healthcare partners, including sample collection kits, lab network access, fulfillment services, and biomarker R&D capabilities across the UK and EU.
Also known as Chronomics
Investors · 2
Company profile
researched Aug 2026Hurdle (hurdle.bio) offers a modular diagnostic infrastructure platform intended to let healthcare and consumer health organisations add or scale laboratory testing without building their own operational stack. The product suite spans biomarker R&D, sample collection kits, lab testing, logistics and fulfilment, a partner dashboard and a digital patient experience layer. For clinics and healthcare providers the platform consolidates diagnostic ordering, results delivery integrated with electronic health records, precision profiles, and administrative workflows into a single system. For consumer and digital medicine brands it supports customised test catalogues, coordinated sample collection, results interpretation and longitudinal health monitoring pathways. For diagnostics companies it provides an end-to-end network and modular processing steps intended to support launching new tests and expanding into additional markets.
Alongside the operational platform, Hurdle markets an AI-driven multi-omics capability aimed at precision medicine, describing the use of multi-modal data at petabyte scale for biomarker discovery and validation, patient stratification and the development of novel clinical endpoints. The company references UKAS-accredited laboratories, clinically validated tests and an in-house science and clinical team as the basis of its scientific claims, and publishes developer documentation, articles and publications.
Integration is offered at several levels of technical sophistication: a unified diagnostics API for teams with engineering resources; Clinics OneDX, a self-contained all-in-one diagnostics ordering system for providers and clinics; a no-code option for standing up a "LabShop" from pre-built templates; and a low-code option for customising workflows and user interfaces with minimal development work.
Business model
Hurdle sells its diagnostic infrastructure to other organisations rather than directly to patients, engaging prospective customers through a contact-sales motion and offering the platform via APIs, a partner dashboard, and packaged low-code and no-code products such as Clinics OneDX and templated LabShops.
▸Full profile — market position, technology, go-to-market
Market position
Hurdle presents itself as an infrastructure provider underpinning the diagnostics operations of clinics, digital health and consumer health companies, diagnostics networks and research organisations.
The company positions its platform as modular and easy to integrate, with a single unified diagnostics interface in place of multiple complex APIs, adoption paths that do not require in-house developers, UKAS-accredited laboratories and clinically validated tests, and an accompanying multi-omics biomarker capability.
Technology
A modular, API-first diagnostics platform covering test ordering, sample collection kits, lab testing, logistics and fulfilment, results delivery with EHR integration and a patient-facing experience layer, plus low-code and no-code configuration options. A separate AI-driven multi-omics component processes multi-modal data described as petabyte scale to support biomarker discovery and validation, patient stratification and new clinical endpoints.
Go-to-market
Direct enterprise sales to partner organisations across defined industry verticals, supported by developer documentation, published articles and publications, and customer stories describing joint deployments.
Healthcare providers and clinics, telehealth companies, consumer healthcare brands, clinical research organisations, employee benefits consultants, diagnostics companies and research institutions.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
▸Research sources · 1
primary sources listed
- Hurdlehurdle.bio · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Hurdle do?
- Hurdle is a diagnostic infrastructure platform that lets healthcare organisations order, integrate and scale lab testing.
- Who are Hurdle's investors?
- Hurdle's investors include Samos Investments, Start Capital.